We are focused on curing HPV with our unique antiviral approach. Our proprietary drug-like compounds target and inactivate a key HPV protein always expressed in early, pre-malignant and cancerous pathologies. By targeting and inactivating this protein, Kovina’s compounds result in the death of HPV infected cells. Our therapeutics are designed to stop HPV infections early before progression and to treat HPV related cancers after detection.
Kovina is committed to providing patients infected with HPV novel treatment options not available in the market today. For patients living with HPV, Kovina’s development efforts provide hope for a non-surgical option to treat cancers and premalignant infections caused by HPV.
Meet the team of leaders and experts behind our science
.jpeg)
.png)
.svg)
A preclinical stage biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV).
